Diana Ernst, RPh, Author at Renal and Urology News

Diana Ernst, RPh

All articles by Diana Ernst, RPh

FDA Approves Hyperkalemia Drug

FDA Approves Mirabegron Solifenacin Combo for OAB

In clinical trials, the combination of Myrbetriq + solifenacin succinate was associated with greater improvements in the number of incontinence episodes per 24 hours (primary endpoint), the number of micturations per 24 hours (primary endpoint), and the volume voided per micturation (secondary endpoint) compared to placebo or to individual active components.

Next post in Overactive Bladder (OAB)